Plasmid DNA fermentation strain and process-specific effects on vector yield, quality, and transgene expression

Biotechnology and Bioengineering

Volumn 108, Issue 2, 2011, Pages 354-363

  Carnes, Aaron E ^a   Luke, Jeremy M ^a   Vincent, Justin M ^a   Schukar, Angela ^a   Anderson, Sheryl ^a   Hodgson, Clague P ^a   Williams, James A ^a  

^a NATURE TECHNOLOGY CORPORATION   (United States)

Author keywords

dcm methylation; DNA vaccine; Fermentation; Gene therapy; Non viral vector; Plasmid

Indexed keywords

COMMERCIAL PRODUCTS; COPY NUMBER; CYTOSINE METHYLATIONS; DCM METHYLATION; DNA VACCINE; HUMAN CELLS; IMMUNOGENICITY; IN-VITRO; MANUFACTURING PROCESS; METABOLIC BYPRODUCTS; NONVIRAL VECTORS; PLASMID; PLASMID DNA; PRODUCTION STRAIN; PRODUCTION YIELD; RECOMBINANT PROTEIN PRODUCTIONS; SPECIFIC EFFECTS; TRANSGENE EXPRESSION; TRANSIENT TRANSFECTION;

ALKYLATION; BIOMOLECULES; CONTRAST MEDIA; DNA; ESCHERICHIA COLI; FERMENTATION; GENE EXPRESSION; GENETIC ENGINEERING; METHYLATION; PRODUCT DEVELOPMENT; VACCINES; VECTORS;

GENE THERAPY;

ACETIC ACID; CYTOSINE; METHYLTRANSFERASE; PLASMID DNA; RECOMBINANT PROTEIN;

ARTICLE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; FERMENTATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; METHYLATION; MOUSE; NONHUMAN; PROMOTER REGION; TRANSGENE;

ACETATES; CULTURE MEDIA; CYTOMEGALOVIRUS; DNA; DNA-CYTOSINE METHYLASES; ESCHERICHIA COLI; FERMENTATION; GENE EXPRESSION; GENETIC VECTORS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; PLASMIDS; TRANSGENES; VACCINES, DNA;

ESCHERICHIA COLI; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 78650213003     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22936     Document Type: Article

References (39)

1. Allamane S, Jourdes P, Ratel D, Vicat JM, Dupré I, Lainé M, Berger F, Benabid AL, Wion D. 2000. Bacterial DNA methylation and gene transfer efficiency. Biochem Biophys Res Commun 276: 1261-1264.
2. 1 DNA sensitive to ribonuclease and alkali. Proc Natl Acad Sci USA 69: 2518-2522.
3. Cai Y, Rodriguez S, Hebel H. 2009. DNA vaccine manufacture: Scale and quality. Expert Rev Vaccines 8: 1277-1291.
4. Carnes AE, Williams JA. 2007. Plasmid DNA manufacturing technology. Recent Pat Biotechnol 1: 151-166.
5. Carnes AE, Williams JA. 2009. Low metabolic burden plasmid production. Genet Eng Biotechnol News 29: 56-57.
6. Carnes AE, Hodgson CP, Williams JA. 2006. Inducible Escherichia coli fermentation for increased plasmid DNA production. Biotechnol Appl Biochem 45: 155-166.
7. Caspeta L, Flores N, Pérez NO, Bolívar F, Ramírez OT. 2009. The effect of heating rate on Escherichia coli metabolism, physiological stress, transcriptional response, and production of temperature-induced recombinant protein: A scale down study. Biotechnol Bioeng 102: 468-482.
8. Collier J. 2009. Epigenetic regulation of the bacterial cell cycle. Curr Opin Microbiol 12: 1-8.
9. Cooke JR, McKie EA, Ward JM, Keshavarz-Moore E. 2004. Impact of intrinsic DNA structure on processing of plasmids for gene therapy and DNA vaccines. J Biotechnol 114: 239-254.
10. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 97: 6640-6645.
11. Dittrich CR, Bennett GN, San KY. 2005. Characterization of the acetate-producing pathways in Escherichia coli Biotechnol Prog 21: 1062-1067.
12. Gomez-Eichelmann MC, Levy-Mustri A, Ramirez-Santos J. 1991. Presence of 5-methylcytosine in CC(A/T)GG sequences (Dcm methylation) in DNAs from different bacteria. J Bacteriol 173: 7692-7694.
13. Haldimann A, Wanner BL. 2001. Conditional-replication, integration, excision, and retrieval plasmid-host systems for gene structure-function studies of bacteria. J Bacteriol 183: 6384-6393.
14. Hornung V, Latz E. 2010. Intracellular DNA recognition. Nat Rev Immunol 10: 123-130.
15. Jeong H, Barbe V, Lee CH, Vallenet D, Yu DS, Choi SH, Couloux A, Lee SW, Yoon SH, Cattolico L, Hur CG, Park HS, Ségurens B, Kim SC, Oh TK, Lenski RE, Studier FW, Daegelen P, Kim JF. 2009. Genome sequence of Escherichia coli B strains REL606 and BL21(DE3). J Mol Biol 394: 644-652.
16. Jiang D, Hatahet Z, Melamede RJ, Kow YW, Wallace SS. 1997. Characterization of Escherichia coli endonuclease VIII. J Biol Chem 272: 32230-32239.
17. Kim YJ, Cha HJ. 2003. Down-regulation of acetate pathway through antisense strategy in Escherichia coli: Improved foreign protein production. Biotechnol Bioeng 83: 841-853.
18. Lahijani R, Hulley G, Soriano G, Horn NA, Marquet M. 1996. High-yield production of pBR322-derived plasmids intended for human gene therapy by employing a temperature-controllable point mutation. Hum Gene Ther 7: 1971-1980.
19. Lai YF, Tseng YJ, Yang FY, Au LC. 2008. Mammalian cis-reporting plasmid may alter activities due to the derivation of host Escherichia coli strains. Anal Biochem 376: 103-107.
20. Lieb M. 1991. Spontaneous mutation at a 5-methylcytosine hotspot is prevented by very short patch (VSP) mismatch repair. Genetics 128: 23-27.
21. Listner K, Bentley L, Okonkowski J, Kistler C, Wnek R, Caparoni A, Junker B, Robinson D, Salmon P, Chartrain M. 2006. Development of a highly productive and scalable plasmid DNA production platform. Biotechnol Prog 22: 1335-1345.
22. Luke J, Carnes AE, Hodgson CP, Williams JA. 2009. Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system. Vaccine 27: 6454-6459.
23. Luke JM, Vincent JM, Du SX, Gerdemann U, Leen AM, Whalen RG, Hodgson CP, Williams JA. 2010. Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers. Gene Ther.
24. Mairhofer J, Cserjan-Puschmann M, Striedner G, Nöbauer K, Razzazi-Fazeli E, Grabherr R. 2010. Marker-free plasmids for gene therapeutic applications-Lack of antibiotic resistance gene substantially improves the manufacturing process. J Biotechnol 146: 130-137.
25. O'Kennedy RD, Ward JM, Keshavarz-Moore E. 2003. Effects of fermentation strategy on the characteristics of plasmid DNA production. Biotechnol Appl Biochem 37: 83-90.
26. Ochiai H, Harashima H, Kamiya H. 2005. Effect of methylated adenine in plasmid DNA on transgene expression in mice. Biol Pharm Bull 28: 2019-2022.
27. Phue JN, Noronha SB, Hattacharyya R, Wolfe AJ, Shiloach J. 2005. Glucose metabolism at high density growth of E. coli B and E. coli K: Differences in metabolic pathways are responsible for efficient glucose utilization in E. coli B as determined by microarrays and Northern blot analyses. Biotechnol Bioeng 90: 805-820.
28. Phue JN, Lee SJ, Trinh L, Shiloach J. 2008. Modified Escherichia coli B (BL21), a superior producer of plasmid DNA compared with Escherichia coli K (DH5α). Biotechnol Bioeng 101: 831-836.
29. Prather KJ, Edmonds MC, Herod JW. 2006. Identification and characterization of IS1 transposition in plasmid amplification mutants of E. coli clones producing DNA vaccines. Appl Microbiol Biotechnol 73: 815-826.
30. Roberts TL, Dunn JA, Terry TD, Jennings MP, Hume DA, Sweet MJ, Stacey KJ. 2005. Differences in macrophage activation by bacterial DNA and CpG-containing oligonucleotides. J Immunol 175: 3569-3576.
31. Singer A, Eiteman MA, Altman E. 2009. DNA plasmid production in different host strains of Escherichia coli J Ind Microbiol Biotechnol 36: 521-530.
32. Stancheva I, Koller T, Sogo JM. 1999. Asymmetry of Dam remethylation on the leading and lagging arms of plasmid replicative intermediates. EMBO J 18: 6542-6551.
33. Trevani AS, Chorny A, Salamone G, Vermeulen M, Gamberale R, Schettini J, Raiden S, Geffner J. 2003. Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol 33: 3164-3174.
34. Tsuchiya H, Matsuda T, Harashima H, Kamiya H. 2005. Cytokine induction by a bacterial DNA-specific modified base. Biochem Biophys Res Commun 326: 777-781.
35. Williams JA, Luke J, Johnson L, Hodgson CP. 2006. pDNAVACC ultra vector family: High throughput intracellular targeting DNA vaccine plasmids. Vaccine 24: 4671-4676.
36. Williams JA. 2008. World Patent Application WO2008153733.
37. Williams JA, Carnes AE, Hodgson CP. 2009a. Plasmid DNA vector design; impact on efficacy, safety and upstream production. Biotechnol Adv 27: 353-370.
38. Williams JA, Luke J, Hodgson CP. 2009b. Strain engineering by genome mass transfer: Efficient chromosomal trait transfer method utilizing donor genomic DNA and recipient recombineering hosts. Mol Biotechnol 43: 41-51.
39. Williams JA, Luke J, Langtry S, Anderson S, Hodgson CP, Carnes AE. 2009c. Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes. Biotechnol Bioeng 103: 1129-1143.